Last reviewed · How we verify
LIPO-102 Low
At a glance
| Generic name | LIPO-102 Low |
|---|---|
| Sponsor | Neothetics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity (PHASE2)
- An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity (PHASE2)
- Dose-ranging Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIPO-102 Low CI brief — competitive landscape report
- LIPO-102 Low updates RSS · CI watch RSS
- Neothetics, Inc portfolio CI